Nulyn Science is deploying proven medicines that interrupt the neuroinflammatory cascade driving postoperative, chemotherapy-induced, and Alzheimer's induced cognitive decline.
Post-operative decline, chemo-related impairment, and Alzheimer's look like different problems. The biology says otherwise: each is initiated by the same neuroinflammatory cascade upstream of synaptic injury. Treat that shared trigger, and one mechanism reaches all three.
Our compounds interrupt this shared cascade upstream of synaptic injury. The full molecular detail — targets, signalling, and data — lives on the science page.
Read the full science →Most efforts to address cognitive decline target its late-stage, behavioral indicators. We treat the trigger: the neuroinflammatory mechanism upstream of synaptic injury — the most tractable, most underexplored target across all three indications.
By leveraging key mechanistic insights and the neuropenetrative characteristics of our lead asset, NS-001, Nulyn Science has set out to improve standards of care for long overlooked conditions, and to address the unmet needs of these widespread indications.
One cascade initiates cognitive decline after surgery, after chemotherapy, and in Alzheimer's. We're building the drugs to interrupt it.
We validate the mechanism first in acute cognitive decline — clear triggers, defined windows of intervention — then extend it to chronic neurodegenerative disease with NS-003, our protected combination compound.
| Programme | Asset | Stage | Status |
|---|---|---|---|
| Post-Operative Cognitive Dysfunction | NS-001 | Phase 2 planned | |
| Chemotherapy-Induced Cognitive Impairment | NS-001 | Expanded access live | |
| Alzheimer's Disease | NS-003 | Pre-clinical |
Stage shown as discovery → pre-clinical → Phase 2 → pivotal.
Full pipeline detail →Both NS-001 and NS-002 are already approved, with established human safety records. The 505(b)(2) repurposing pathway lets us move on validated biology — far faster, at far better odds, than developing a new molecule from scratch. Our novel compound NS-003 combines the two — giving us strong reason to expect it inherits their safety profiles and high tolerability.
Nulyn Science is advancing NS-001 to Phase 2 in POCD and CICI, and taking NS-003, our Alzheimer's combination, through IND-enabling pre-clinical studies. Validated mechanisms, existing safety data, and novel IP. View teaser deck for the full plan.